Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his ...

Australian healthcare sector leaders believe while progress has been made further work is needed to see more women in senior ...

Special Report: Dimerix has received the initial payment of ¥300 million (A$3.2 million) in line with its recently announced ...

Dimerix Ltd (ASX:DXB) has confirmed its receipt of its first $3.2 million payment from Japan’s FUSO Pharmaceutical Industries ...

Healthcare analysts believe that shares in rare neurological share play Neuren Pharmaceuticals are well undervalued after a ...

Dimerix Limited ( ($AU:DXB) ) has provided an update. Dimerix Limited has announced the quotation of 147,275 ordinary fully paid securities on the ...

Investor reaction to PolyNovo's (ASX:PNV) half-year numbers shows how even seemingly minor earnings misses can result in a ...

In a report released on February 21, Tanushree Jain from Petra Capital maintained a Buy rating on Dimerix Limited (DXB – Research Report), with ...

The Middle East healthcare sector is undergoing rapid expansion presenting opportunities for ASX-listed pharmaceutical medical device and wellness companies.

Dimerix pursues new product concepts and applies scientific knowledge to the discovery of products from early stage development through to commercialisation.

Highlights,Recruitment begins for the first paediatric patient in a pivotal kidney disease trial.,19 specialist sites across multiple countries involved in the paediatric study plan.,Interim data ...

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.